Q3 EPS Forecast for Protara Therapeutics Cut by Analyst

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Protara Therapeutics in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.36) per share for the quarter, down from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.50) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at $0.56 EPS and FY2030 earnings at $1.09 EPS.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03).

Other equities analysts have also issued research reports about the company. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. JPMorgan Chase & Co. dropped their target price on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Oppenheimer raised their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Protara Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $26.25.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.94 on Friday. Protara Therapeutics has a 52-week low of $2.97 and a 52-week high of $7.82. The stock has a fifty day moving average price of $4.03 and a two-hundred day moving average price of $5.03. The company has a market cap of $232.85 million, a price-to-earnings ratio of -2.92 and a beta of 1.50.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds have recently bought and sold shares of the stock. AIGH Capital Management LLC purchased a new stake in Protara Therapeutics during the first quarter valued at $8,454,000. UBS Group AG boosted its holdings in shares of Protara Therapeutics by 44.2% during the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock valued at $6,479,000 after purchasing an additional 372,463 shares during the last quarter. Walleye Capital LLC increased its stake in Protara Therapeutics by 204.0% in the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock worth $2,310,000 after acquiring an additional 297,525 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Protara Therapeutics by 133.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock worth $2,767,000 after acquiring an additional 304,110 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in shares of Protara Therapeutics by 81.0% in the fourth quarter. Baker BROS. Advisors LP now owns 971,614 shares of the company’s stock worth $5,179,000 after purchasing an additional 434,782 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.